ArticleInternational journal of clinical oncology2021

Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study.

Koichi Kido et al.PubMed ↗Publisher ↗

No numbers read from the abstract.